A phase I study of HEC73543, an oral FLT3 inhibitor: the effect of food on pharmacokinetics after oral dosing in healthy Chinese volunteers

Clicks: 58
ID: 283868
2025
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #264 of 309 articles by views in Frontiers in pharmacology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 309 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
ObjectiveThis study evaluated the effect of food on the pharmacokinetics (PK) and safety of HEC73543.MethodsThis randomized, open-label, single-dose, phase I parallel trial included 40 healthy subjects randomized (1:1) to either high-fat or fasted groups. Participants received a single oral dose of 40 mg HEC73543. Blood samples were collected and detected using a validated liquid chromatography tandem mass spectrometry method. PK parameters were calculated using non-compartmental methods. Safety was monitored throughout the study.ResultsFor the HEC73543, the fed-to-fasted ratios were: area under the curve from time 0 to time t (AUC0–t), 219.42% (90% confidence interval [CI]: 173.76, 277.08%); AUC from zero to infinity (AUC0–∞), 255.22% (90% CI: 198.10, 328.80%); and maximum concentration (Cmax), 221.31% (90%CI: 190.57, 257.00%). Similarly, for the metabolite M3, the fed-to-fasted ratios were: AUC0–t, 190.86% (90%CI: 153.26%, 237.68%); AUC0–∞, 190.29% (90% CI: 151.77%, 238.59%); and Cmax, 177.48% (90% CI: 137.80%, 228.58%). Median Tmax of HEC73543 were comparable between the two groups. The most frequently Treatment-Related Adverse Events (TRAEs) were elevated blood triglycerides, oral ulceration, hyperuricemia, diarrhea, thoracalgia. Most TRAEs were Grade 1 or 2.ConclusionHigh-fat food intake enhanced bioavailability and increases the systemic exposure levels of HEC73543 and its metabolite M3.Clinical Trial RegistrationNCT05454098 (http://www.clinicaltrials.gov/).
Reference Key
imported_1760285568_68ebd38020031 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ding, Yanhua
Journal Frontiers in pharmacology
Year 2025
DOI
10.3389/fphar.2025.1636504
URL
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1636504/full
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.